Research Advisory Council (RAC)


PCC is advised and counseled by a Research Advisory Council (RAC) that comprises prominent prostate cancer researchers. The role of RAC is to:
  • Synthesize the results of the peer review process and make recommendations for funding to senior PCC staff
  • Receive reports of the evaluation of PCC research programs and provide advice on the development of new programs and the ongoing improvements to existing programs
  • Lead the identification of strategic research areas that could be targeted with specific Requests For Applications
  • Evaluate the PCC peer review processes and recommend necessary enhancements on an ongoing basis
  • Recommend membership of peer review panels
  • Identify potential national and international opportunities for collaboration
  • Provide advice in the development and refinements of scientific and administrative policies
The Council will be composed of established prostate cancer researchers who:
  • Collectively represent expertise in all areas of prostate cancer research
  • Are broadly representative of all major regions in Canada
  • Individually have a strong track record in peer-reviewed research funding and research output
In addition, the Council will include 2 non-scientific members, one of whom must be a prostate cancer patient or survivor. Each will be identified and selected through a formal nomination process.

Current Membership

David Berman, Queen's Cancer Research Institute, Kingston, ON
Paul Boutros, Ontario Institute for Cancer Research (OICR), Toronto
, ON
Ralph Buttyan, Vancouver Prostate Centre, Vancouver, BC
Kim Chi, BC Cancer Agency, Vancouver, BC
Michael Cox, University of British Columbia, Vancouver, BC

Stuart Edmonds (Ex Officio), Prostate Cancer Canada, Toronto, ON
Carolyn Gotay, University of British Columbia, Vancouver, BC
Masoom Haider, Sunnybrook Research Institute, Toronto
, ON
Winston Klass, Community Representative, Concord, ON
John Lewis, University of Alberta, Edmonton, AB
Randy Mellow, Community Representative, Peterborough, ON

Ian G.Mills, Queen's University Belfast, Belfast, UK
John Oliffe, University of British Columbia, Vancouver
, BC
Marie-Elise Parent, INRS–Institut Armand-Frappier Research Centre, Laval, QC
Fred Saad, Université de Montréal, Montreal, QC
Gurmit Singh (Scientific Chair), McMaster University, Hamilton, ON

John Valliant, McMaster University, Hamilton, ON
Danny Vesprini, Sunnybrook Research Institute, Toronto, ON

As of June 26, 2017

 

Call for Nominations 2018

 
Prostate Cancer Canada has been successful in supporting important, innovative research to improve the understanding of, and the effects of prostate cancer on men. The Research Advisory Council (RAC) has played a pivotal role in this. RAC ensures Prostate Cancer Canada funds only the research that has the greatest potential to impact this disease by identifying research priorities, overseeing the peer-review process and advising on PCC’s ongoing research projects and awards. With the release of the PCC Research Strategic Plan in 2012, under the guidance of RAC, great progress has been made in launching important research projects that have generated new knowledge and have the potential to have a large impact on the management of prostate cancer. As PCC is continuing to deploy innovative research programs, we are soliciting nominations for RAC membership to maintain momentum.
 
Specifically PCC is seeking individuals who:

 

  • are established independent health researchers with a focus or interest in prostate cancer
  • possess a clear understanding and demonstrated leadership experience of peer review processes for research funding
  • have a strong track record in peer-reviewed research grant funding and research output
  • have an understanding of how to evaluate the impact of health research programs
  • have knowledge of the Canadian health research funding landscape
  • preferably have experience in a research strategic advisory role in another organization
 
Each term of appointment is 3 years, renewable for a further term. Collectively RAC membership represents expertise in all areas of health research and is broadly representative of all major regions of Canada.
 
RAC meets in person at least once each year. Other meetings will take place by teleconference as needed. Members will be reimbursed for reasonable travel and accommodation expenses according to PCC’s travel policies. 
 

To Apply
 
Please send the following to constitute your nomination for membership to Prostate Cancer Canada’s Research Advisory Council:
  • a letter of interest introducing the nominee and  qualifications for this role
  • an abridged Curriculum Vitae (include information from only the previous five years)

Self-nominations are permitted.
 

Please send your nomination documents to Stephanie Bazinet, Coordinator, Research at research@prostatecancer.ca no later than Wednesday, February 28, 2018. 
Appointments will be confirmed in early April.

 
 


Plaid for Dad


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More

Landmark study links tumour evolution to prostate cancer severity

Toronto (April 19, 2018) – Findings from Canadian Prostate Cancer Genome Network (CPC-GENE) researchers and their collaborators, published today in Cell, show that the aggressiveness of an individual prostate cancer can be accurately assessed by looking at how that tumour has evolved.
More


Click here for news archive